Table 1 Baseline demographics and disease characteristics of patients with sJIA and pcJIA (radiographic and study populations)
Characteristic | sJIA | pcJIA | ||||
|---|---|---|---|---|---|---|
Adapted SH, n = 47 | Poznanski, n = 33 | All, n = 112 | Adapted SH, n = 45 | Poznanski, n = 35 | All, n = 188 | |
Age, years | 9.9 (4.3) | 8.4 (4.2) | 9.7 (4.6) | 10.8 (3.7) | 9.9 (3.3) | 11.0 (4.0) |
Female, n (%) | 24 (51) | 13 (39) | 56 (50) | 34 (76) | 27 (77) | 144 (77) |
Race, white, n (%) | 43 (91) | 29 (88) | 99 (88) | 33 (73) | 25 (71) | 150 (80) |
Body weight, kg | 33.7 (15.7) | 28.2 (14.5) | 33.8 (19.6) | 39.3 (16.3) | 36.3 (14.7) | 39.6 (17.3) |
Disease duration, years | 5.2 (4.2) | 4.8 (4.1) | 5.2 (4.1) | 3.9 (3.3) | 3.2 (2.4) | 4.2 (3.7) |
Joints with active arthritisa | 21.3 (15.7) | 19.2 (16.5) | 19.8 (15.7) | 20.9 (13.7) | 21.7 (14.5) | 20.3 (14.3) |
Joints with LOMb | 20.0 (15.7) | 18.2 (16.7) | 19.8 (15.6) | 14.8 (12.0) | 16.3 (13.0) | 17.6 (14.4) |
Patient/parent global assessment VASc | 55.4 (22.7) | 55.6 (25.1) | 58.7 (24.4) | 42.5 (26.3) | 41.9 (26.4) | 52.9 (25.0) |
Physician global assessment VASc | 62.3 (19.5) | 62.8 (20.0) | 64.9 (22.3) | 57.2 (19.8) | 59.1 (18.4) | 61.4 (20.7) |
CHAQ-DI score (0–3) | 1.6 (0.9) | 1.6 (0.9) | 1.7 (0.9) | 1.3 (0.6) | 1.3 (0.5) | 1.4 (0.7) |
ESR, mm/h | 53.9 (31.5) | 59.2 (35.2) | 57.6 (34.2) | 29.9 (22.3) | 30.9 (21.9) | 34.8 (25.5) |
Previous DMARDs use, n (%) | 34 (72) | 22 (67) | 82 (73) | 31 (69) | 20 (57) | 134 (71) |
Previous biologic use, n (%) | 39 (83) | 26 (79) | 92 (82) | 9 (20) | 7 (20) | 61 (32) |
Background methotrexate use, n (%) | 34 (72) | 28 (85) | 77 (69) | 39 (87) | 30 (86) | 148 (79) |
Methotrexate dose, mg/m2/week | – | – | – | 12.5 (3.3) | 12.7 (3.3) | 13.0 (5.8) |
Background oral GC use, n (%) | 23 (49) | 12 (36) | 55 (49) | 19 (42) | 15 (43) | 86 (46) |
GC dose, mg/kg/dayd | 0.28 (0.17) | 0.31 (0.16) | 0.30 (0.20) | 0.13 (0.05) | 0.14 (0.05) | 0.13 (0.05) |